5Verma A, Solomon SD. Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist [ J ]. Curr Heart Fail Rep, 2007,4(4) :183-189.
6Rathmann W, Haastert B, Roseman JM, et al. Cardiovascular drug prescriptions and risk of depression in diabetic patients [J]. J Clin Epidemiol, 1999,52 ( 11 ) : 1103-1109.
8Guex JJ,Zimmet SE, Boussetta S, et al. Construction and validation of a patient-reported outcome dedicated to chronic venous disorder: SQOR-V (specific quality of life and outcome response-venous ). J Mal Vasc, 2007,32(3 ) : 135-147.
9U. S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for Industry Pa- tient-Reported Outcome Measures:Use in Medical Product Development to Support Labeling Claims. Health and Quality of Life Outcomes ,2006, 4(1) :1-20.
10Hunt SM, McKenna SP, McEwen J, et al. The Nottingham Health Profile: subjective health status and medical consultations. Soc SciMed, 1981,15( 13Pt1) :221-229.
